{{위키데이터 속성 추적}}
{{Infobox drug|drug_name=|legal_status=|legal_UK_comment=<ref>{{웹 인용| title=Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=8 July 2020 | url=https://www.medicines.org.uk/emc/product/9694 | access-date=1 October 2020}}</ref>|legal_US=Rx-only|legal_US_comment=<ref name="Delstrigo FDA label" />|legal_EU=Rx-only|legal_EU_comment=<ref name="Delstrigo EPAR">{{웹 인용| title=Delstrigo EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo | access-date=1 October 2020}}</ref>|legal_UN=<!-- N I, II, III, IV / P I, II, III, IV-->|legal_NZ=<!--Class A, B, C -->|routes_of_administration=|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|synonyms=MK-1439A

<!-- Identifiers -->|CAS_number=2446159-50-6|ATCvet=|ATC_prefix=J05|ATC_suffix=AR24|PubChem=|DrugBank=|legal_UK=POM|legal_BR_comment=|type=combo|tradename=Delstrigo|component1=도라비린|class1=비뉴클레오사이드 [[역전사효소 억제제]]|component2=라미부딘|class2=뉴클레오사이드 [[역전사효소 억제제]]|component3= 테노포비르 디소프록실|class3=뉴클레오사이드 [[역전사효소 억제제]]

<!-- Clinical data -->|pronounce=|Drugs.com={{drugs.com|monograph|doravirine-lamivudine-and-tenofovir-disoproxil-fumarate}}|legal_BR=<!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->|MedlinePlus=a618049|DailyMedID=Delstrigo|pregnancy_AU=<!-- A/B1/B2/B3/C/D/X -->|pregnancy_US=<!-- A/B/C/D/X -->|pregnancy_category=|legal_AU=S4|legal_AU_comment=|KEGG=D11396}}

'''도라비린/라미부딘/테노포비르'''(제품명: Delstrigo)는 [[후천면역결핍증후군|후천 면역 결핍증]]을 치료하기 위한 고정 용량의 항레트로바이러스 복합제제이다.<ref name="Delstrigo FDA label">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd1e9f84-607a-46d3-b01e-2736018d67b6|title=Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated|date=10 October 2019|website=DailyMed|access-date=31 July 2020}}</ref><ref name="CADTH">{{저널 인용|title=Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)|journal=CADTH Common Drug Reviews|url=https://www.ncbi.nlm.nih.gov/books/NBK544820/|date=June 2019|location=Ottawa (ON)|pmid=31393687|vauthors=((Canadian Agency for Drugs and Technologies in Health))}}</ref> 위 약물은 [[도라비린]], [[라미부딘]]과 [[테노포비르 디소프록실]] 성분이 조합되어 있다.<ref name="Merck">{{보도자료 인용|title=FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients|publisher=Merck & Co.|url=https://www.businesswire.com/news/home/20180830005793/en/FDA-Approves-Merck%E2%80%99s-DELSTRIGO%E2%84%A2-doravirine-lamivudine-tenofovir|date=30 August 2018}}</ref><ref name="CADTH" /> 2018년 8월, HIV-1 감염에 대한 치료제로 미국 [[미국 식품의약국|FDA]]로부터 승인받았다.<ref name="Merck" /><ref>{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210807Orig1s000ltr.pdf|title=Delstrigo approval letter|date=2018-08-30|publisher=[[Food and Drug Administration]] (FDA)|access-date=10 September 2019}}</ref><ref>{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000,210807Orig1s000TOC.cfm|title=Drug Approval Package: Pifeltro (doravirine)|date=9 October 2018|website=U.S. [[Food and Drug Administration]] (FDA)|access-date=22 September 2020}}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==

* {{웹 인용|url=https://druginfo.nlm.nih.gov/drugportal/name/doravirine|title=Doravirine|work=Drug Information Portal|publisher=U.S. National Library of Medicine}}
* {{웹 인용|url=https://druginfo.nlm.nih.gov/drugportal/name/lamivudine|title=Lamivudine|work=Drug Information Portal|publisher=U.S. National Library of Medicine}}
* {{웹 인용|url=https://druginfo.nlm.nih.gov/drugportal/name/tenofovir%disoproxil|title=Tenofovir disoproxil|work=Drug Information Portal|publisher=U.S. National Library of Medicine}}
* {{웹 인용|url=https://druginfo.nlm.nih.gov/drugportal/name/tenofovir%20disoproxil%20fumarate|title=Tenofovir disoproxil fumarate|work=Drug Information Portal|publisher=U.S. National Library of Medicine}}
* {{웹 인용|url=https://www.cadth.ca/doravirine-lamuvidine-tenofovir-disoproxil-fumarate|title=doravirine lamuvidine tenofovir disoproxil fumarate|publisher=[[Canadian Agency for Drugs and Technologies in Health]] (CADTH)}}

{{항레트로바이러스제}}

[[분류:항레트로바이러스 복합제]]